📊 CMPS Key Takeaways
Is COMPASS Pathways plc (CMPS) a Good Investment?
COMPASS Pathways is a pre-commercial clinical-stage biopharmaceutical company with zero revenue and negative operating cash flow of -$47.9M annually. While the company maintains a fortress balance sheet with $466M in cash and minimal debt, it is purely executing on R&D with no near-term profitability path and faces significant regulatory approval risk on psilocybin therapies.
COMPASS Pathways shows very weak current fundamentals: it remains pre-revenue, deeply unprofitable, and consumed $119.45M of operating cash over the latest period. While the company still holds a sizable cash balance, its thin equity base, negative returns, and ongoing burn make the financial profile highly dependent on future clinical and financing success rather than operating strength.
COMPASS Pathways plc Key Strengths (CMPS)
- Exceptional cash reserves of $466M provide 10+ year runway at current burn rate
- Very strong balance sheet with 0.15x debt-to-equity ratio and 3.32x current ratio
- Positioned in high-growth psychedelic-assisted therapy market with significant unmet medical need
- Cash and equivalents of $185.94M provide near-term liquidity support
- Current and quick ratios of 1.23x indicate the company can currently meet short-term obligations
- Minimal capital expenditure requirements suggest an asset-light operating model
CMPS Stock Risks: COMPASS Pathways plc Investment Risks
- Zero revenue with company in pre-commercial clinical development stage
- Negative operating cash flow of -$47.9M; company burning cash with no offsetting revenue
- Regulatory uncertainty for psilocybin therapies; approval not guaranteed and timelines unpredictable
- Negative EPS trends (-0.30, down 33.9% YoY) with no clear profitability inflection point
- Dilutive equity financing likely required if development timelines extend or commercialization is delayed
- No revenue base and large net loss of $193.98M indicate no proven earnings power
- Operating cash outflow of $119.45M implies limited cash runway if burn remains elevated
- Very weak balance sheet quality, with only $37.59M of equity, ROE of -516.0%, and negative interest coverage
Key Metrics to Watch
- Clinical trial progress and regulatory pathway updates for COMP360 psilocybin therapy
- Quarterly cash burn rate and cash runway (currently consuming ~$48M annually)
- R&D spend efficiency and timeline to potential FDA approval or license agreements
- Quarterly operating cash burn relative to cash balance
- Clinical progress and any revenue-generating commercialization or partnership milestones
COMPASS Pathways plc (CMPS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.32x current ratio provides a solid financial cushion.
CMPS Profit Margin, ROE & Profitability Analysis
CMPS vs Healthcare Sector: How COMPASS Pathways plc Compares
How COMPASS Pathways plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is COMPASS Pathways plc Stock Overvalued? CMPS Valuation Analysis 2026
Based on fundamental analysis, COMPASS Pathways plc appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
COMPASS Pathways plc Balance Sheet: CMPS Debt, Cash & Liquidity
CMPS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: COMPASS Pathways plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.30 indicates the company is currently unprofitable.
CMPS Revenue Growth, EPS Growth & YoY Performance
COMPASS Pathways plc Dividends, Buybacks & Capital Allocation
CMPS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for COMPASS Pathways plc (CIK: 0001816590)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 29, 2026 | 4 | xslF345X06/wk-form4_1780090300.xml | View → |
| May 29, 2026 | 4 | xslF345X06/wk-form4_1780090009.xml | View → |
| May 29, 2026 | 4 | xslF345X06/wk-form4_1780089449.xml | View → |
| May 29, 2026 | 4 | xslF345X06/wk-form4_1780089389.xml | View → |
| May 29, 2026 | 4 | xslF345X06/wk-form4_1780089227.xml | View → |
❓ Frequently Asked Questions about CMPS
What is the AI rating for CMPS?
COMPASS Pathways plc (CMPS) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CMPS's key strengths?
Claude: Exceptional cash reserves of $466M provide 10+ year runway at current burn rate. Very strong balance sheet with 0.15x debt-to-equity ratio and 3.32x current ratio. ChatGPT: Cash and equivalents of $185.94M provide near-term liquidity support. Current and quick ratios of 1.23x indicate the company can currently meet short-term obligations.
What are the risks of investing in CMPS?
Claude: Zero revenue with company in pre-commercial clinical development stage. Negative operating cash flow of -$47.9M; company burning cash with no offsetting revenue. ChatGPT: No revenue base and large net loss of $193.98M indicate no proven earnings power. Operating cash outflow of $119.45M implies limited cash runway if burn remains elevated.
What is CMPS's revenue and growth?
COMPASS Pathways plc reported revenue of N/A.
Does CMPS pay dividends?
COMPASS Pathways plc does not currently pay dividends.
Where can I find CMPS SEC filings?
Official SEC filings for COMPASS Pathways plc (CIK: 0001816590) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CMPS's EPS?
COMPASS Pathways plc has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CMPS's fundamental grade?
Based on our AI fundamental analysis in June 2026, COMPASS Pathways plc has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CMPS stock overvalued or undervalued?
Valuation metrics for CMPS: ROE of 27.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is CMPS's AI grade for 2026?
Our dual AI analysis gives COMPASS Pathways plc a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CMPS's free cash flow?
COMPASS Pathways plc's operating cash flow is $-47.9M, with capital expenditures of $0.0.
How does CMPS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE 27.9% (avg: 15%), current ratio 3.32 (avg: 2).
Why is CMPS's return on equity (ROE) so high?
COMPASS Pathways plc has a return on equity of 27.9%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity.